Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD

University of Cologne110 enrolled

Overview

To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

110

Conditions

Macular Degeneration

Interventions

RanibizumabDRUG

upload (three monthly injections), re-treatment as needed

Eligibility

Sex: ALLMin age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * active subfoveal CNV related to exudative age-related macular degeneration (all subforms) * age \> 60 years * visual acuity \> 20/400 * no previous treatment for AMD Exclusion Criteria: * any previous AMD therapy * other CNV types (myopic, parapapillary) * contraindication for ranibizumab treatment * prior study participation for AMD * pregnancy / premenopausal women

Locations (1)

University Center of Ophthalmology

Cologne, North Rhine-Westphalia, Germany

Outcomes

Primary Outcomes

Visual acuity

Change in visual acuity within the observation period

Time frame: 2 years

Secondary Outcomes

Association between treatment response and genotype

Time frame: 2 years

Changes in OCT central retinal thickness / retinal volume

Time frame: 2 years

Association between treatment application delay and visual outcome

Time frame: 2 years

Association between re-treatment necessity / frequency and intraocular cytokine profiles

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.